

*On page 9, lines 20 to 21, please replace with:*

---**FIG. 19** are nucleotide sequences of the remaining 3' portion of rat CCK promoter and amino acid (**SEQ. ID. NO. 16**) and nucleotide sequences of human growth hormone (**SEQ. ID. NO. 17**).---

*On page 9, line 22, please replace with:*

---**FIG. 20** is the sequence for the rat GIP promoter from -1 to -1894 bp (**SEQ. ID. NO.19**).---

### **REMARKS**

The application and claims have been amended to refer to updated sequence identifiers in conjunction with Applicant's response to the Notice to Comply mailed January 16, 2003. A marked-up copy of the original page of the application bearing the modified paragraph reflect the amendments in red ink.

Submitted herewith are substitute paper and computer readable copies of the Sequence Listing. An executed statement under 37 C.F.R 1.821(f) and (g) that the paper and computer readable copies of the Sequence Listing are identical and that the substitute Sequence Listing does add new matter is submitted herewith.


The amendments to the specification to add sequence identifiers and the Sequence Listing were made to correct several informalities. As such no new matter has been added and entry of the amendments and Sequence Listing is respectfully requested.

If the fee authorized is incorrect or if any other fees are due in connection with this submission, please charge any such fee or credit any overpayment to Deposit Account No. 03-3975.

Respectfully submitted,

Pillsbury Winthrop LLP

By: \_\_\_\_\_

  
Robert M. Bedgood

Reg. No.: 43,488

Tel. No.: (858) 509-4065

Fax No.: (858) 509-4010